In updated Phase 1/2 data from 31 sickle cell disease patients treated with ristoglogene autogetemcel (risto-cel; formerly BEAM-101), mean fetal hemoglobin exceeded 60%, hemoglobin S fell below 40%, and anemia resolved across the cohort, with durability up to 20.4 months. No investigator-reported severe vaso-occlusive crises occurred post-engraftment. Median neutrophil and platelet engraftment times were 17.5 and 19 days, respectively; 29% of patients required no platelet transfusions. Editing levels in peripheral blood averaged 67.4% at six months and 72.8% at 12 months. One death occurred four months post-infusion, deemed likely related to busulfan conditioning rather than the edited product.
The core development is Beam’s ASH presentation of safety, efficacy, and manufacturability readouts from BEACON alongside an operational update: a median of one stem cell collection cycle and three total collection days enabled product manufacture plus backup collections. The company also highlighted a tiered fixed-dose plerixafor strategy that increased CD34+ yields and reduced collection cycles versus weight-based dosing, positioning mobilization as a controllable variable in a notoriously brittle ex vivo workflow. The program has been renamed to risto-cel and remains on track to complete dosing in this Phase 1/2 study ahead of regulatory interactions.
Strategically, Beam is pressing the case that base editing can deliver both biologic and operational advantages in a market already reshaped by approvals of exagamglogene autotemcel and lovotibeglogene marcelpivocel. By editing the HBG promoter to displace BCL11A binding without cutting DNA, risto-cel aims to drive pancellular HbF with fewer double-strand-break liabilities and more predictable product attributes. The emphasis on predictable yields, fewer apheresis cycles, and rapid engraftment is not a side note: it targets the bottlenecks that have constrained throughput and planning across cell therapy centers. The counterweight is familiar: busulfan myeloablation remains the clinical and perception-limiting risk in this modality, as underscored by the fatal event attributed to conditioning.
For sites, a median single collection cycle and faster mobilization could translate into fewer apheresis chair-days, tighter scheduling, and reduced collection failure risk. Shorter neutropenia windows and lower platelet use lighten inpatient resource loads and transfusion logistics, which matters as transplant programs struggle to scale gene therapy volumes. For sponsors and CROs, a fixed-dose mobilization schema simplifies protocols and may reduce screen failures and manufacturing attrition, improving slot utilization and CMC predictability. Regulators will focus on durability beyond 24 months, genomic safety specific to base editors, and whether clinical outcomes like VOE elimination and hemolysis normalization hold across subgroups. Payers will parse inpatient days, transfusion intensity, and re-hospitalizations as leading indicators for total cost of care relative to approved autologous options.
The near-term watchlist is clear. Durability past two years and comprehensive off-target and RNA-editing analyses will shape the benefit-risk narrative for base editing in hemoglobinopathies. Conditioning remains the largest friction point; any credible path to antibody-based or reduced-toxicity regimens would materially alter adoption curves. Operationally, Beam will need to demonstrate that fixed-dose mobilization and high editing rates hold at scale, with minimal bridging chemistry, manufacturing, and controls changes between Phase 1/2 and pivotal supply. Endpoint selection will also matter: hard VOE outcomes versus HbF-centric composites will determine comparability to the current standards and influence review timelines. Finally, capacity partnerships with high-volume transplant centers and clear time-to-discharge metrics will be the practical differentiators in a market where efficacy signals now cluster near the ceiling and execution is the variable that decides share.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
New Hope in Hematology: Sickle Cell, AML and Leukemia Trial Updates - Get Healthy Fx
9 months ago[…] 🔗 Read more: BEAM’s Risto-Cel Shows Durable Profile in Sickle Cell Trial […]